EUVIMED · CrossrefZeitschrift
Clinical Lymphoma and Myeloma
ISSN 1557-9190 · Elsevier BV
Neueste Artikel
Selected Clinical Trials in Diffuse Large B-Cell Lymphoma and T-Cell Lymphoma
Abstracts From: Hematologic Malignancies 2009 Brussels, Belgium September 30 – October 3, 2009
CME Test
We Should Have a Dream: Unlocking the Workings of the Genome in Cutaneous T-Cell Lymphomas
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma
Serum Levels of Total-RANKL in Multiple Myeloma
Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse
Favorable Consolidative Effect of High-Dose Melphalan and Total-Body Irradiation Followed by Autologous Peripheral Blood Stem Cell Transplantation After Rituximab-Containing Induction Chemotherapy With In Vivo Purging in Relapsed or Refractory Follicular Lymphoma
Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Granulomatous Slack Skin: Assessment of Disease Progression and Treatment Response Using Positron Emission Tomography/Computed Tomography
Behçet's Disease in a Patient With Myelodysplastic Syndrome
Bing-Neel Syndrome: A Case Report and Systematic Review of Clinical Manifestations, Diagnosis, and Treatment Options
The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy
Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab
Yttrium-90 Microsphere Radioembolization of the Spleen: A New Approach for the Treatment of Malignant Lymphomatous Splenomegaly
Metronomic Cyclophosphamide and Vinblastine in Refractory Lymphoma
Concomitant or Sequential Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML): A Molecular and Clinical Survey
The Impact of Selected Apoptotic Markers and Adhesion Molecules on the Treatment Outcome of Chronic Lymphocytic Leukemia
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab
Complex Immunophenotypic Changes as Prognosis Panel in Chronic Lymphocytic Leukemia
Valproic Acid, a Histone Deacetylase Inhibitor, Induces Apoptosis, Inhibits Proliferation, and Synergizes With Chemotherapy: The Rationale to Combine it for the Treatment of B-Cell Chronic Lymphocytic Leukemia
Outcome of First Salvage Therapy in Patients With Chronic Lymphocytic Leukemia Relapsing After First-line Fludarabine, Cyclophosphamide, and Rituximab
Coexistence of a JAK2 Mutated Clone May Cause Hematologic Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Kinetics of Molecular Response to Imatinib in Patients With Chronic Myeloid Leukemia May Predict Persistent Polymerase Chain Reaction Negativity After Imatinib Discontinuation
Feasibility and Safety of Maintenance Therapy in the Treatment of Acute Myeloid Leukemia
Current Diagnostic Approach in Acute Myeloid Leukemia in the Republic of Macedonia: A Proposal for Minimal Screening-Based Clinical Stratification
Is Platelet Aggregation a Useful Investigation in Assessing the Risk of Thrombosis in Patients With JAK-Positive Chronic Myeloproliferative Disorders? Brief Report: A Study on 14 Patients
Chronic Myeloid Leukemia: Where Do We Go Now?
EUVIMED